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Abstract
Background: Implementing organizations are pressured to be accountable for performance. Many health impact
metrics present limitations for priority setting; they do not permit comparisons across different interventions or
health areas. In response, Population Services International (PSI) adopted the disability-adjusted life year (DALY)
averted as its bottom-line performance metric. While international standards exist for calculating DALYs to
determine burden of disease (BOD), PSI’s use of DALYs averted is novel. It uses DALYs averted to assess and
compare the health impact of its country programs, and to understand the effectiveness of a portfolio of
interventions. This paper describes how the adoption of DALYs averted influenced organizational strategy and
presents the advantages and constraints of using the metric.
Methods: Health impact data from 2001-2011 were analyzed by program area and geographic region to measure PSI’s
performance against its goal of doubling health impact between 2007-2011. Analyzing 10 years of data permitted
comparison with previous years’ performance. A case study of PSI’s Asia and Eastern European (A/EE) region, and PSI/
Laos, is presented to illustrate how the adoption of DALYs averted affected strategic decision making.
Results: Between 2007-2011, PSI’s programs doubled the total number of DALYs averted from 2002-2006. Most
DALYs averted were within malaria, followed by HIV/AIDS and family planning (FP). The performance of PSI’s A/EE
region relative to other regions declined with the switch to DALYs averted. As a result, the region made a strategic
shift to align its work with countries’ BOD. In PSI/Laos, this redirection led to better-targeted programs and an
approximate 50% gain in DALYs averted from 2009-2011.
Conclusions: PSI’s adoption of DALYs averted shifted the organization’s strategic direction away from product sales
and toward BOD. Now, many strategic decisions are based on “BOD-relevance,” the share of the BOD that
interventions can potentially address. This switch resulted in more targeted strategies and greater program
diversification. Challenges remain in convincing donors to support interventions in disease areas that are relevant
to a country’s BOD, and in developing modeling methodologies. The global health community will benefit from
the use of standard health impact metrics to improve strategic decision making and more effectively respond to
the changing global burden of disease.
Background
Program impact and the cost effectiveness of investments
in health interventions are pressing concerns among glo-
bal health organizations, due to an environment of
decreasing resources. Donors and implementing organi-
zations are increasingly asked to demonstrate value for
money, prompting the use of health metrics to show
quantifiable results. Donors use health metrics to moni-
tor and evaluate the performance of their recipients and
to inform their investments. Implementing organizations
use metrics to measure program success, document best
practices, and report back to donors on performance.
The larger global health community - which includes
donors and implementers as well as researchers and pol-
icy makers - uses metrics to inform its discussions and
identify each stakeholder’s role in health promotion.
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The pressure on implementing organizations to be
accountable for performance is increasing. Recently, the
United States Agency for International Development,
the Global Fund, the United Kingdom’s Department for
International Development, and the World Bank have
adopted performance-based funding systems to reward
programs that deliver positive health outcomes, while
reducing aid to organizations that do not [1-4]. To
prioritize program development and improve decision
making, standard measurement processes and agreement
on which health metrics best address the majority of the
global health community’s concerns are needed [5-7].
In the past, health impact has typically been expressed
through metrics such as cases averted and deaths
averted for interventions preventing disease acquisition
or progression. Calculations for cases and deaths averted
are disease specific and can be applied to any health
area where the outcome includes mortality, including
HIV/AIDS, sexually transmitted infections (STIs), diar-
rheal diseases, maternal health, and malaria [8-10].
Another metric, couple-years of protection (CYPs), has
been used to estimate the impact of FP products and
services [11,12]. While useful for disease-specific inqui-
ries, these metrics pose a major challenge for priority
setting: they do not permit comparisons across different
interventions or health areas to inform decision making
based on potential health impact.
Summary measures of population health (SMPH) are
more comprehensive than the aforementioned metrics:
they provide convenient, single-unit snapshots of a par-
ticular health situation in a given context. Murray and
Lopez identified eight uses of SMPH for improved deci-
sion making: comparing health status across various
populations; comparing health status of the same popu-
lation over time; identifying health inequalities among
populations; accounting for the burden of nonfatal
health outcomes and not simply mortality; setting prio-
rities for health services improvements; setting priorities
for health research and development; improving public
health training curricula; and analyzing the cost-effec-
tiveness of health promotion programs [13,14]. SMPH
combine all relevant health information about a popula-
tion into a bottom-line measure that can be used with
stakeholders [15].
This paper focuses on one particular SMPH, the dis-
ability-adjusted life year. The World Bank and World
Health Organization (WHO) developed the DALY in
1993 to address the need for SMPH that account for
mortality and morbidity, as well as provide objective
information about population health status for decision
making [7,16,17]. DALYs have been preferred to other
“gap measures” because they allow morbidity and mor-
tality to be disaggregated into years of life lost and years
of life lost due to disability [18]. The result is a metric
that combines the value of lives saved with illness and
disability prevented.
The most common use of DALYs is to estimate the
BOD in a population. The WHO Global Burden of Dis-
ease uses DALYs to demonstrate where certain diseases
are concentrated and where health areas have been dispro-
portionately addressed, particularly at the national level
[19,20]. DALYs are a convenient unit of measurement
because researchers and decision makers can disaggregate
results by region, sex, age group, and disease type. Estima-
tion of health burden using DALYs also enables users to
detect key differences across populations [21,22].
Researchers and implementers frequently apply DALYs to
estimate BOD for health conditions perceived as neglected
in order to garner funding and program support from
donors and policy makers [23-29].
Like other metrics, DALYs can also be used along with
cost data to estimate the cost-effectiveness of health inter-
ventions by simply dividing overall costs by health impact,
the number of DALYs averted by the intervention. Cost-
effectiveness is a critical input to strategic decision making,
particularly when interventions are life saving, but costs
vary greatly between strategies. Cost-effectiveness analyses
using cost per DALY averted have become standard for
health programs in low- and middle-income countries
[30-42].
This paper describes why one international non-
governmental organization (INGO), Population Services
International, adopted the DALY as its bottom-line esti-
mate for health impact. It describes how the organiza-
tion uses DALYs averted for strategic decision making
at the global, regional, and country levels, and relates
how the adoption of this metric had a profound impact
on PSI’s strategic direction. The paper also presents the
advantages and practical constraints of using DALYs
averted to optimize an organization’s health impact and
offers considerations for using the metric in the future.
PSI’s history of health impact measurement
PSI is an INGO that uses social marketing to improve the
health status of the poor and vulnerable in developing
countries. By adapting marketing strategies and methods
developed in the for-profit sector, PSI helps those in need
adopt healthy behaviors. PSI has also modeled its manage-
ment practices on the for-profit sector, creating an organi-
zational culture where there is a strong focus on its
bottom line, a discrete set of metrics that quantify organi-
zational achievement. Since performance management
goals for programs, as well as individual staff, are tied to
this organization-wide measure, program staff actively
work to maximize their contributions and increase the
bottom line.
For its first two decades, PSI measured its bottom line
by the number of products sold. Since the organization
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worked primarily on FP, sales of contraceptives were
also converted into CYPs. During these early years,
many meetings among senior decision makers revolved
around the monthly sales report, which compiled activ-
ities from all PSI interventions. While reviewing sales
reports is a simplistic way to view programmatic pro-
gress by today’s standards, the process did help identify
areas of high and low performance. More importantly,
this use of metrics helped the organization think more
strategically by looking beyond individual intervention
deliverables to focus on building “programs,” portfolios
of interventions that would deliver value over the long
term.
In the 1980s and mid-1990s, PSI introduced other
programs into its portfolio, including diarrheal disease
(early 1980s), HIV/AIDS (late 1980s), and malaria (early
1990s). In the late 1990s, PSI adopted Person-Years of
Protection (PYP), a new, simple conversion factor, to
estimate the number of person-years protected by the
number of health product units sold or distributed.
While the PYP allowed PSI to create an aggregate bot-
tom-line measure, its utility was limited. The PYP did
not estimate health impact; rather, it expressed sales
using a common denominator for interventions of dif-
ferent durations. Therefore, this metric did not allow
decision makers to see differences in the potential health
impact across interventions. It also did not include esti-
mates of effectiveness and gave equal weight to all pro-
ducts distributed. Finally, the PYP was specific to PSI,
which did not allow the organization to compare its per-
formance to that of other implementation organizations.
To address the limitations of PYPs, PSI adopted
DALYs averted as its key performance metric in 2006.
DALYs averted counts the number of DALYs that are
not lost, but averted, by a health intervention. By using
DALYs averted, the organization could estimate the
health impact of its products, services, and behavior
change interventions across all of its health areas. These
results, in turn, would inform strategic decision making.
While international standards existed to calculate DALYs
at the national level for determining BOD, PSI’s use of
DALYs averted was novel. It used DALYs averted to
measure the effectiveness of a portfolio of interventions
and to estimate the health impact of those interventions.
Basing a metric on the DALY offered several advantages
for estimating organizational health impact. The DALY is
a recognized unit for measuring BOD, which ensures
alignment with the international public health community.
It also enables PSI to measure the impact of all of its inter-
ventions and in relation to BOD, which rewards and rein-
forces targeted interventions. PSI can combine this impact
with cost for internal comparisons of its interventions’
cost-effectiveness as well as to compare its costs with
other INGOs and against global standards. Additionally,
the DALY permits comparisons of impact across different
health conditions and across countries.
It is important to note that while the DALY captures
information on maternal and child mortality and morbid-
ity, it does not capture the full contribution of FP inter-
ventions. Namely, the DALY does not include the
protection from unplanned pregnancies and birth spacing
provided by FP methods. For this reason, PSI continues
to measure FP program impact with CYPs, the standard
global metric for family planning. CYPs serve as a com-
plementary measure to DALYs averted, each capturing
different impacts of PSI’s FP products and services.
With the switch to DALYs averted as its key perfor-
mance metric, PSI made the strategic decision to double
its global health impact in five years, from 2007-2011.
This goal and the adoption of the DALYs averted metric
aligned and motivated PSI’s staff operating in 67 coun-
tries, either through its own country offices or through
locally governed affiliates. The DALYs averted measure
was factored into individual performance goals, annual
appraisals, and incentive compensation, in addition to
the country and regional operating plans.
Methods
To use DALYs averted as its primary health impact mea-
sure, PSI developed several models. These models estimate
the impact of a range of preventive and therapeutic inter-
ventions for seven specific health areas: HIV/AIDS and
other STIs, FP, maternal health (e.g., abortion, clean deliv-
ery practice, and micronutrient deficiencies), child health
(e.g., nutrition, acute respiratory infection, and diarrhea),
malaria, tuberculosis (TB), and cervical cancer. Most
model parameters come from one of four data sources:
Demographic Health Surveys, United Nations Population
Division, WHO, or Multiple Indicator Cluster Surveys.
When parameters are unknown, modelers use assump-
tions based on the published literature or, when necessary,
PSI country experiences. Specific details about the model
parameters and methodology, together with specific exam-
ples of two of PSI’s DALYs averted models, are found in
another paper in this supplement [43].
Through stochastic modeling, DALYs averted models
produce coefficients that are, effectively, the estimated
number of DALYs averted by a single product unit (e.g.,
a condom) in a single country. Each month, PSI esti-
mates health impact from the sales, distribution, and
service utilization (collectively referred to forthwith as
“distribution”) figures reported by each of the country
offices. These figures are multiplied by country-level
coefficients to determine the number of DALYs averted
by each intervention. When products provide multiple
years of effectiveness (e.g., long-lasting, insecticide-trea-
ted bednets (LLINs), the multi-year impact is credited
during the year in which the products are distributed.
Longfield et al. BMC Public Health 2013, 13(Suppl 2):S2
http://www.biomedcentral.com/1471-2458/13/S2/S2
Page 3 of 13
PSI also estimates the impact of its product and ser-
vice promotion efforts done in collaboration with part-
ners. To avoid “over-claiming” impact, PSI counts only
partial impact from results stemming from these part-
nerships, according to policies developed by an internal
working group of researchers, modelers, technicians,
and implementers. For example, the service referral pol-
icy applies to interventions in which PSI generates
demand for health services, but does not actually deliver
the service, such as adult male circumcision, intrauterine
device (IUD) insertions, or HIV testing and counseling.
Successful referrals are counted as 50% of the health
impact from that service. The significant involvement
policy describes how much health impact can be
counted from activities in which PSI plays a role in pro-
duct procurement, communication, and distribution, but
is not entirely responsible for product delivery. When
PSI participates in a subset of these activities with part-
ners, that subset can be counted toward DALYs averted.
PSI has applied this policy to its large-scale, LLIN distri-
bution campaigns in which PSI collaborated with part-
ners to distribute LLINs, but did not actually place the
nets directly into the hands of recipients.
Finally, PSI estimates the impact of its behavior change
communication (BCC) activities on non-product beha-
viors and the use of non-PSI brands. Doing so is impor-
tant for interventions that do not require a product, like
the reduction of sexual partners for HIV prevention, or
when PSI interventions promote the use of a category of
products, such as condoms, rather than simply the use of
its own brands. To correlate behavior change with expo-
sure to PSI interventions, PSI uses population-based sur-
vey data. When a significant correlation is detected, PSI
estimates the size of the population covered, multiplies it
by the exposure rate, and estimates the number of new
infections averted. These new infections averted are then
converted into DALYs averted. Currently, PSI has seven
models to estimate DALYs averted through exposure to
BCC activities.
Thus, in the most basic terms:
PSI’s overall estimate of health impact = (DALYs
averted coefficients * PSI distribution) + Service Referral
DALYs averted + Significant Involvement DALYs
averted + DALYs averted through BCC
Keeping the DALYs averted models current is an
ongoing process. As new or more relevant evidence
becomes available, PSI revises its models to ensure that
its calculations are as accurate as possible. Revised coef-
ficients are applied yearly and adjustments to the models
directly affect PSI’s bottom line. When appropriate,
changes are applied retrospectively; for example, when
WHO revises its BOD figures. The health impact in any
given year may increase or decrease depending on the
models’ magnitude of change.
PSI applies the most recent model coefficients when
calculating its health impact on a monthly basis. Senior
managers at all levels of the organization - global, regio-
nal, and country - use these results to monitor progress
against intended targets and to guide strategic decision
making. They identify areas for improvement and redir-
ect program and funding priorities as needed.
For this paper, PSI’s health impact data over the last
10 years (2001-2011) were compiled and analyzed by
program area and geographic region in order to demon-
strate PSI’s progress in achieving its strategic goal of
doubling health impact between 2007 and 2011. Show-
ing 10 years of data enables comparison with the years
preceding this decision. To generate DALYs averted and
standardize annual comparisons, distribution figures for
each year were multiplied by the most up-to-date coun-
try-level DALYs averted coefficients (2011 coefficients at
the time of writing). Following these results, a case
study is presented to illustrate how the adoption of
DALYs averted as PSI’s primary health impact metric
affected decision making at the regional level and then
within one country in that region.
Results
Between 2007 and 2011, PSI distributed billions of pro-
ducts and services throughout its worldwide operations.
Table 1 presents distribution figures for products and
services that accounted for the majority (90%) of the
organization’s health impact during this time. Two pro-
ducts - LLINs and male condoms - account for 75% of
this health impact. Over the course of this five-year per-
iod, PSI distributed nearly 114 million LLINs and five
billion condoms.
Figure 1 portrays PSI’s health impact as measured in
DALYs averted over the course of 10 years. Different
colors in the bar charts indicate the health areas in
which impact was achieved.
Between 2002 and 2006, PSI averted a total of 30.5
million DALYs, with a compound growth rate of 28.7%.
The organization then established the goal of doubling
its health impact between 2007 and 2011. During this
time there was a marked increase in the total number of
DALYs averted. By the end of 2011, PSI had doubled its
health impact, averting 22.8 million DALYs in that year.
From 2007-2011, 79.7 million total DALYs were averted,
with a compound growth rate of 26.6% each year.
Most DALYs averted were in malaria, which
accounted for 58% of PSI’s overall health impact
between 2007-2011. In addition to the high volumes of
product distribution, the multi-year effectiveness for
LLINs (three years for every net distributed) also helped
rapidly increase the number of DALYs averted in
malaria, particularly given that this multi-year impact
was credited in the year the nets were distributed.
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Changes in resource flows influenced PSI’s decision
making. The Global Fund, for example, invested heavily
in LLINs for malaria prevention during this period.
Combined with PSI’s shift to a BOD-focused strategy,
this change in donor priorities made it easier for PSI to
recognize that rapid gains in health impact could be
achieved by changing its approach from one of sales
through commercial channels to one that included free
distribution campaigns. A narrower view about the role
of PSI as a social marketing organization would have
left too much health impact unrealized. As a result,
approximately 58% of PSI’s health impact in 2007-2011
was from the distribution of free products, namely
LLINs and condoms, which means that product sales
stopped growing during this period and free distribution
became more important for PSI to achieve its bottom
line.
The dip in PSI’s health impact in 2010 is primarily
explained by large LLIN distribution campaigns in coun-
tries with lower malaria burdens than those in preceding
and subsequent years. Countries with the greatest LLIN
distribution over the course of five years were Kenya
and the Democratic Republic of Congo with more than
15 million LLINs distributed in each, followed by Mada-
gascar (9.8 million) and Côte d’Ivoire, Uganda, and
Cameroon, which each received more than eight million
LLINs from PSI distribution channels. By 2011, PSI was
also distributing artemisinin-based combination thera-
pies (ACTs) in 12 countries and rapid diagnostic tests in
five countries, contributing to additional health impact
Table 1 Product distribution, 2007-2011, in number of units and percentage of DALYs averted














LLINs 8,539,211 16,367,864 19,025,760 26,564,490 43,413,442 113,910,767 46%
Condoms 973,626,161 1,092,370,452 1,175,647,927 1,266,880,272 1,297,766,426 5,806,291,238 29%
Malaria pre-packaged therapy
(ACTs)
339,593 3,713,502 9,379,305 10,796,682 11,438,863 35,667,945 5%
Insecticide retreatment for
bednets*
2,770,513 5,636,933 5,022,990 1,428,482 272,854 15,131,772 4%
Oral contraceptives 25,060,192 28,595,110 30,187,839 38,336,016 38,272,868 160,452,025 2%
HIV counseling and testing 807,813 1,158,011 1,569,736 1,833,415 1,414,591 6,783,566 2%
IUDs** 284,127 349,704 618,082 613,595 567,199 2,432,707 1%
Basic Care Package for people
living with HIV/AIDS
75,648 60,493 352,708 757,187 17,349,693 18,595,729 1%
* Either bundled with malaria nets (not LLINs) or distributed alone
** Figures are for IUD distribution only. PSI counts IUD insertions through its service delivery sites differently, applying a higher DALYs averted coefficient.
Figure 1 PSI’s global health impact, 2002-2011, in DALYs averted, by health area.
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in malaria. All of these prevention and treatment inter-
ventions produced a compound annual growth rate of
44.4% for DALYs averted in malaria between 2007 and
2011.
While a distant second to malaria, HIV/AIDS also
experienced steady gains in health impact, increasing at an
annual compound growth rate of 7.3% between 2007 and
2011. Increases in HIV DALYs averted were primarily due
to extensive condom distribution programs in all three of
PSI’s African regions. Male circumcision programs also
contributed to gains in HIV/AIDS health impact, following
its launch in Zambia in 2007 and expansion to another
four countries by 2011. The marginal decline in HIV
health impact in 2011 is largely attributed to stock outs of
free condoms in South Africa.
Health impact within PSI’s FP programs steadily
increased over the course of 2007-2011, with the greatest
gains in the last four years. Condom distribution
accounted for the bulk of these increases, which factors
into both HIV/AIDS and FP DALYs averted due to con-
doms’ role in dual protection. Grants from an anon-
ymous donor to increase IUD insertions and implants
also played a role. The DALYs averted compound growth
rate from 2007-2011 in FP was 11.6% each year. During
the same period, the organization generated 80.4 million
CYPs, with the greatest increase in 2010 and 2011. (Note:
CYPs are not featured in Figure 1.)
While PSI achieved small strides with other interven-
tions, such as safe water solution (e.g., chlorination), oral
rehydration salts (ORS), and pneumonia pre-packaged
therapy (PPT), these products contributed very little to
PSI’s overall health impact due to limited distribution.
They accounted for only 3% of PSI’s total DALYs averted
between 2007 and 2011. Of these products, PPT shows
the greatest promise for health impact, but, so far, PSI’s
distribution has been limited to just five countries. Addi-
tionally, directly observed therapy, short-course (DOTS)
for TB shows promise as a contributor to DALYs averted,
but PSI’s role in distribution is currently limited to only
three countries. In terms of nutrition interventions, only
PSI/Pakistan has received funding for one nutrition pro-
duct (Sprinkles) at present.
Strategic changes in Asia and Eastern European region
from the use of DALYs averted
PSI’s decision to measure organization-wide impact
using DALYs averted challenged managers to frame
their decisions about strategy, implementation, fundrais-
ing, and performance goals in relation to BOD across
the regions in which it operates. The Asia and Eastern
European (A/EE) region, and one of the countries within
it, Laos, offer an instructive example of how the use of
DALYs averted affected strategic decisions.
PSI is organized into five regions: 1) West and Cen-
tral Africa, 2) East Africa, 3) Southern Africa, 4) Asia
and Eastern Europe, and 5) Latin America and the Car-
ibbean. Each region develops a strategy that is consis-
tent with PSI’s global strategy while respecting varying
contexts. Regions are accountable for health impact
goals set on an annual basis and monitored throughout
the year. As a result, regional directors and country
managers develop their intervention strategies and
evaluate new funding opportunities based on their
potential to contribute to the bottom line in terms of
health impact.
Under the measurement system of PSI’s early years -
one based on sales and CYPs - PSI’s A/EE region was a
relatively high performer, mainly due to large contracep-
tive social marketing programs in India and Pakistan that
sell high volumes of condoms and oral contraceptives.
Well-funded programs in Cambodia and Myanmar also
made substantial contributions to the regional bottom
line. The switch to PYPs had a modest effect on A/EE’s
relative performance in 2002 and 2003, but as PSI started
to scale up malaria programming in sub-Saharan Africa,
the relative performance of the region declined (Figure 2).
The switch to DALYs averted had an even greater
impact on the region’s relative performance. While A/
EE averted a total of 5.3 million DALYs from 2007-
2011, this achievement represented, on average, just 7%
of the organization’s overall health impact. The A/EE
region’s five-year compound growth rate was 11.7%,
with the largest increases in child survival and malaria
product distribution (30.5% and 20.9%, respectively). By
comparison, PSI’s country offices in Africa averted more
than 74 million DALYs during the same period, with a
five-year compound growth rate of 28%. Figure 3 por-
trays the DALYs averted in both of these regions over
the course of 10 years.
Thus, the “success” that Asia and Eastern Europe had
experienced from its FP programs when it relied on
sales and CYPs was diminished: lower BOD from mater-
nal mortality, perinatal conditions, and HIV/AIDS in
Asia meant lower health impact from condoms and
modern contraception when PSI adopted DALYs
averted as the bottom-line metric. It quickly became
clear to managers that meeting the need for HIV pre-
vention and modern contraception in India did not have
the same impact as meeting that need in Nigeria where
HIV prevalence and maternal mortality are higher.
Some managers in the A/EE region initially viewed the
switch to DALYs averted with skepticism, especially
those who thought the metric undervalued the region’s
FP work since it did not capture protection from
unplanned pregnancies and the benefits of birth spacing.
Others argued that the approach did not adequately
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value intervening early in an HIV epidemic and with key
populations at risk - that is, before the emergence of the
high prevalence, generalized epidemic that resulted in
high DALYs averted in Africa. Still others, seeing low
health impact figures for their programs, paid less atten-
tion to PSI’s bottom line and continued to focus on pro-
cess level indicators, which had always been important
to the majority of donors and monitored as deliverables
under individual interventions.
Managers also realized that many of PSI’s programs in
A/EE were simply not that relevant to the disease burden
in each country. Globally, PSI works heavily in HIV pre-
vention and malaria - despite lower disease burdens in
Asia and Eastern Europe - because donor resources are
focused on those areas at present. Working in those dis-
ease areas in Africa addresses a substantial part of that
continent’s disease burden. But the shift to DALYs averted
pushed the A/EE region toward greater examination of
Figure 3 PSI’s global health impact, 2002-2011, in DALYs averted, by region. *PSI’s interventions in Latin America and the Caribbean are
smaller than those in other regions of the world, with an average of 65,000 DALYs averted per year between 2002 and 2011. The narrow
orange strip at the top of the bar graphs represents this region’s contribution to PSI’s global health impact.
Figure 2 Contribution of PSI’s A/EE Region to global impact, 2002-2011, in PYPs and DALYs averted*. *PYPs were used as the
performance metric from 2002-06 and DALYs averted from 2007-11.
Longfield et al. BMC Public Health 2013, 13(Suppl 2):S2
http://www.biomedcentral.com/1471-2458/13/S2/S2
Page 7 of 13
BOD, revealing that country offices needed to be concen-
trating more on areas like TB diagnosis and treatment as
well as non-communicable diseases (NCDs), such as
hypertension and smoking-related conditions.
As a result, the A/EE region reformulated its strategy
around BOD and included a “relevance” metric in its
regional plan in 2010, which meant that a country pro-
gram’s performance would be measured, in part, by the
share of the BOD that its interventions could potentially
address. The region began identifying funding sources,
and designing and implementing interventions in more
relevant high BOD areas. The A/EE region also started
integrating existing interventions with high BOD inter-
ventions; for example, HIV service offerings were com-
bined with TB case detection and treatment. Regional
discussions and meetings focused on “relevance” with
participation from global experts knowledgeable in
higher BOD areas. Expertise in higher BOD areas was
also increasingly a factor in the recruitment of new staff
at the country program level. Additional gains in strat-
egy have been the introduction of interventions in
tobacco control, hypertension, and cervical cancer in
A/EE. PSI has also invested resources into expanding its
efforts in facility-based interventions, in recognition of
the need for quality medical service provision when
addressing these new disease areas.
Impact of the adoption of DALYs averted on PSI/Laos
strategy
PSI started operations in Laos in 1999. During its first 10
years, PSI/Laos focused primarily on HIV and malaria pre-
vention, with product distribution of male condoms and
LLINs serving as the primary measure of success. This
emphasis on sales succeeded in making condoms and
malaria nets widely available in the country. Continuing
the distribution of existing products was the easiest way to
boost sales, rather than investing time in launching pro-
ducts or services in new, unfamiliar health areas.
The switch to DALYs averted as PSI’s primary metric
of health impact in 2006 revealed how limited PSI/Laos’
impact had been, in terms of reducing the existing
BOD. Each year in Laos, HIV/AIDS and malaria cause
the loss of 2,398 and 2,571 DALYs, respectively. By con-
trast, there is a high concentration of DALYs lost every
year in four other health areas that PSI/Laos was not
working on: lower respiratory infections, especially from
pneumonia (134,654 DALYs); unmet need for FP
(239,969 DALYs from maternal and perinatal condi-
tions); nutritional deficiencies (84,792 DALYs); and TB
(31,448 DALYs)(Figure 4). Confronted with these BOD
figures, PSI/Laos began to view its interventions differ-
ently and made a fundamental shift in its strategic direc-
tion, focusing less on expanding sales and distribution of
condoms and LLINs, and more on launching interven-
tions in these four new health areas.
Securing funding to launch such interventions was, and
continues to be, a difficult task. The main public health
donors for Laos were primarily supporting interventions
in certain communicable diseases, such as HIV and
malaria, and not providing funds for TB or maternal and
child health issues such as pneumonia, nutrition, and
diarrheal disease. The PSI/Laos team spent much time
and effort trying to interest donors in funding new inter-
ventions. By the end of 2010, PSI/Laos secured funding
from WHO, Global Fund, and private foundations for
three high burden areas: FP, maternal health, and TB.
New capacity-building interventions in the private sector
aimed to strengthen the Laos health system by providing
access to long-term FP methods, misoprostol to reduce
postpartum hemorrhage, TB case detection, and DOTS
treatment. Monies allocated for these important health
areas now comprise approximately half of PSI/Laos’ total
Figure 4 Burden of disease in Laos (WHO, 2004).
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current funding in country, a major shift from 2010 when
all of PSI/Laos’ funding was for HIV/AIDS and malaria.
Despite this progress, funding for other areas, including
pneumonia and diarrheal disease, remain elusive. For
those health areas, the PSI/Laos team continues to sub-
mit concept notes to donors and is working hard along-
side the Laos government, WHO, United Nations, and
others to stimulate interest in funding these high BOD
areas.
Shifting to more BOD-"relevant” program areas also
required a significant adjustment among PSI/Laos’ inter-
nal staff and external stakeholders who had been accus-
tomed to working primarily on HIV/AIDS and malaria
programs. Staff had to develop skills appropriate for the
new health area interventions. In some cases, new staff
had to be recruited, especially those with clinical skills,
to ensure the correct provision of TB DOTS and long-
term FP methods.
Paying close attention to DALYs averted rather than
product distribution also changed day-to-day program
implementation at PSI/Laos. The team reexamined its
interventions and how they were implemented, especially
questioning the value of ever-expanding sales of existing
products for HIV and malaria prevention. The result was
a program portfolio of much better targeted and higher
quality interventions. For example, HIV/AIDS interven-
tions were increasingly targeted to key populations at
higher risk of HIV/AIDS and STIs, such as men who
have sex with men and female sex workers. Condoms are
still widely distributed, but condom promotion efforts
focus more on key populations, those who need them
most for prevention of HIV and STIs. Thus, while annual
condom distribution numbers dropped considerably for
the general population (from about eight million con-
doms in 2008 to about four million in 2010), rates of
condom use among key populations actually rose,
according to behavioral surveys [44]. PSI/Laos also
improved and diversified its HIV interventions beyond
condoms; for example, it launched a network of volun-
tary counseling and testing sites to increase HIV testing
and expand STI screening. On the malaria side, rather
than simply trying to expand the sales and distribution of
LLINs, PSI/Laos worked closely with the Ministry of
Health to re-design the malaria intervention with a focus
on more targeted net delivery to villages with the highest
rates of malaria.
The health impact generated by PSI/Laos during this
transition period reflects the country program’s readjust-
ment process. Between 2007 and 2011, PSI/Laos hov-
ered among those PSI countries producing the lowest
number of DALYs averted. PSI/Laos recorded a negative
overall compound annual growth rate (-2.3%), with
annual DALYs averted ranging from 4,439 (the low
point, in 2009) to 9,905 (the high point, in 2008). This
low impact is largely due to PSI/Laos’ more targeted
efforts in HIV and more time focused on securing new
donor funding in the high BOD areas, actions which
resulted in a decreased number of condoms in its “pipe-
line,” and therefore, a reduction in health impact. Since
condoms provide dual protection against HIV/AIDS and
unplanned pregnancy, this distribution shift meant that
PSI/Laos’ health impact declined in two health areas, HIV/
AIDS and FP. With the shift toward high BOD areas, a
focus on long-term contraceptive methods, and additional
targeting within HIV/AIDS and malaria, PSI/Laos has
slowly, but steadily, increased its DALYs averted. Begin-
ning in 2011, PSI/Laos started to see the impact of its
long-term FP method distribution and, while modest, its
first DALYs averted from TB interventions. As a result,
annual DALYs averted in 2011 increased approximately
50% over its total from 2009, as the focus on high burden
areas began to show real impact. Steady growth in overall
health impact is expected to continue in coming years
(Figure 5).
Discussion
Using DALYs averted as its bottom-line metric has been
valuable for increasing PSI’s scope and improving its strate-
gic direction. This measure moved the organization from a
counting exercise (sales and PYPs) to a more rigorous and
meaningful approach of measuring impact in relation to
BOD. Product distribution is still a vital part of the PSI
toolbox, but its deployment is now more strategic, based
on what the organization learned by applying DALYs
averted to measure impact. Using this metric also per-
mitted alignment with the international public health com-
munity. PSI can now compare health impact across the
different health areas and countries in which it works as
well as prioritize its areas of focus across the organization.
PSI’s strong focus on malaria prevention and LLIN dis-
tribution proved essential in helping the organization
achieve its five-year goal of doubling health impact. While
this focus was influenced by resource flows, PSI’s prioriti-
zation of BOD opened up new possibilities for applying its
expertise in distribution. These efforts averted more than
36 million DALYs between 2007 and 2011 from the
malaria disease burden in the countries where PSI works.
Such high impact is due to the scale of the organization’s
LLIN distribution for malaria prevention, the multiple
years of protection provided by LLINs, as well as PSI’s
work in countries where the burden of malaria is highest,
primarily in sub-Saharan Africa.
At the same time, as seen in the case of PSI/Laos,
using DALYs averted as the organization’s bottom-line
metric exposed the need to focus on other high BOD
areas and to strategically diversify some country offices’
program portfolios - a long-term gain for PSI and for
the vulnerable populations experiencing heavy BOD. As
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a result, all PSI country offices are now more careful
when choosing health areas and funding sources.
Setting a clear, performance objective for the organiza-
tion and tying country office and individual performance
goals to the organization’s goal of doubling health
impact helped align staff around the DALYs averted
metric. Country offices where program portfolios were
not aligned with BOD, such as PSI/Laos, chose to redir-
ect their efforts to new health areas with higher BOD
rather than only concentrating on longstanding inter-
ventions in health areas with low disease burden. Even
though PSI/Laos experienced losses to health impact in
the short term while it made this transition, greater
health impact in higher priority health areas is already
being recorded. Such growth will likely continue over
the medium to long term. These strategic shifts are now
being replicated in other parts of the organization. Most
importantly, PSI has identified BOD - and an individual
country’s specific BOD - as one of the main drivers
behind its program efforts going forward.
Aligning a large INGO around the DALYs averted
metric was not without its challenges, many of which
are ongoing. A key challenge is the model development
process itself. Building and maintaining tailored DALYs
averted models for each intervention proved demanding,
particularly given PSI’s evidence-based approach and its
broad scope of work with over 60 different products
and services. The organization’s one full-time modeler
and two consultants struggled to keep up, especially
when new products, interventions, and populations were
introduced. Important lessons were also learned about
the limitations of specifically tailored models. PSI’s
DALYs averted models have been constructed for single
interventions at a static point in time and cannot be
used to consider combined effects, competing risks, or
trade-offs between different intervention options.
Moreover, while DALYs averted is a strong metric for
capturing information on morbidity and mortality, it
does not capture all of PSI’s work. DALYs averted does
not include the full contribution of PSI’s FP interven-
tions, so the organization continues to use CYPs as a
complementary measure to estimate the impact of its FP
products and services. Capturing the health impact of
non-PSI brands and behavior change communication
for non-product behaviors (such as number of sexual
partners) requires population-based surveys, and beha-
vior change must be attributed to PSI’s interventions in
order to claim DALYs averted.
The DALYs averted models, like all models, are only as
good as the data used to develop them. Data availability
is an important limitation. Where data on effectiveness
(the measured use of a product or service and its impact
on a population) are available, the models take these into
account; where data are not available, PSI relies on esti-
mates of efficacy, and measured impact from controlled
field trials. At the time of writing, PSI’s models used
WHO BOD estimates from 2004; they will be updated
when country-specific BOD data are available in 2013.
Therefore, PSI’s decision making in the last five years
could have been based on out-of-date estimates of BOD,
which would affect its ability to target impact and the
relevance of new programs. Reliance on distribution fig-
ures as a proxy for product use is a particular challenge;
PSI adjusts for wastage in the supply chain (as a general
rule, 15% through outlets and 5% through service pro-
viders) and compliance in cases where it is required
and feasible (e.g., LLINs and ACTs). In most cases, it is
impossible to know the profile of populations who
Figure 5 PSI/Laos’ health impact, 2002-2011, in DALYs averted, by health area.
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purchased or received commodities. As a result, the
added benefit of targeting key populations, such as pro-
viding female sex workers with condoms, is not taken
into account unless a population-based survey is used to
estimate the uptake by key populations. Additional data
compromises are the inclusion of neighboring country
data or regional averages when no local data are available
in places where PSI works (e.g., South Sudan and Somali-
land). In the absence of reliable data or literature, PSI
develops best estimates based on experience for some
model parameters, such as supply chain wastage.
Working in new disease areas will increase the pressure
on modelers to either produce more new models or adapt
existing burden of disease tools from other agencies. Now,
PSI is considering new and more efficient methods for
modeling health program impact, such as the Lives Saved
Tool and the Spectrum Modeling System that consolidates
several different models into one integrated package
[45-47]. In the meantime, PSI is collaborating with other
organizations like Marie Stopes International to align
DALYs averted model parameters and assumptions. It is
also collaborating with cross-agency working groups to
adopt standard metrics and improve their use for decision
making. As the responsibility of creating tailored models is
likely beyond the capacity of most INGOs, the develop-
ment of more standardized modeling methodologies, as
well as alignment on standard health impact measure-
ment, will benefit the wider global health community.
PSI is also developing methods to calculate cost per
DALYs averted in real time so that cost-effectiveness data
can be used alongside DALYs averted and BOD to influ-
ence decision making. Harmonizing accounting processes
and finding methods to apportion costs has been a chal-
lenge. When combined with information about the scale
of programs and potential reach, cost-effectiveness data
will help optimize investment strategies. Such efforts will
be the subject of future publications.
There are two important issues that any organization
estimating its health impact must consider. The first is
attribution. It is important to acknowledge that impact
is a shared responsibility and donors and partners work-
ing together all contribute to DALYs averted. Shared
ownership of health impact should preclude organiza-
tion-specific claims to attribution. Likewise, organiza-
tions should think carefully about the DALYs averted
they count, especially when their role is limited to refer-
rals into a larger health system or product distribution
on behalf of other partners. PSI addresses attribution
through its internal working group, which creates poli-
cies to prevent over-claiming health impact. The second
issue is substitution, which DALYs averted does not
account for; the DALYs averted models treat new users
and those who switch product brands or health provi-
ders in the same manner. As a result, it is important to
track expanding markets for products and services in a
different way. PSI strives to expand health markets and
increase use through a total market approach, which
relies on a different set of performance metrics.
In terms of advocacy, PSI faces a number of chal-
lenges due to its new prioritization of BOD. Chief
among these is convincing global health funding organi-
zations to support interventions in disease areas outside
of those they currently fund. While some funding exists
for undernutrition, diarrheal disease, maternal health,
and other recognized developing world health condi-
tions, fewer global health donors currently support
interventions in tobacco control, cervical cancer, hyper-
tension, and other non-communicable diseases. Regions
such as A/EE and Latin America will need to add NCDs
to their program portfolios in order to have increased
health impact. West and Central Africa may be success-
ful by introducing new child survival programs, includ-
ing interventions that prevent or treat acute respiratory
infections.
PSI has begun educating stakeholders about these con-
cerns, particularly in relation to the BOD in some of the
regions it serves, as well as by identifying new donors.
While PSI has been successful in getting new donors on
board, its strategic shift has also forced its country offices
to make hard choices in order to match its work to the
actual BOD. In 2010 and 2011, for example, PSI/Laos
passed over opportunities for new funding in HIV/AIDS
and malaria, preferring to focus on securing donor support
in the high burden disease areas. Now, PSI/Laos no longer
operates a malaria prevention program. This country office
is in the process of scaling up new interventions in FP,
reproductive health, and TB, positioning it favorably to
achieve greater health impact in the future.
Conclusion
PSI’s adoption of DALYs averted as its measure of health
impact had a profound effect on the organization’s strate-
gic direction and scope, shifting the focus away from pro-
duct sales and more toward BOD. Switching to a more
robust health metric has produced a more targeted strat-
egy. It also prompted greater diversification in interven-
tions and country programs, and allowed the organization
to be responsive to potential funding sources and alterna-
tive distribution strategies. Using a bottom-line metric
such as DALYs averted can improve interventions and
their impact, innovations that global health organizations
will need to embrace in response to shifts in the global
burden of disease.
List of abbreviations
PSI: Population Services International; DALY: disability-adjusted life year; BOD:
burden of disease; A/EE: Asia and Eastern European region; HIV/AIDS: human
immunodeficiency virus/acute immune deficiency syndrome; FP: family
Longfield et al. BMC Public Health 2013, 13(Suppl 2):S2
http://www.biomedcentral.com/1471-2458/13/S2/S2
Page 11 of 13
planning; STIs: sexually transmitted infections; CYPs: couple-years of
protection; SMPH: summary measures of population health; WHO: World
Health Organization; INGO: international non-government organization; PYP:
Person-Year of Protection; TB: tuberculosis; LLIN: long-lasting, insecticide-
treated net; IUD: intrauterine device; BCC: behavior change communication;
ACT: artemisinin-based combination therapy; ORS: oral rehydration solution;
PPT: pneumonia pre-packaged therapy; DOTS: directly observed treatment,
short-course; NCDs: non-communicable diseases
Authors’ contributions
KL designed the study and drafted the manuscript. BS drafted the regional
case study. RG drafted the Laos case study. LN conducted data analysis,
prepared all tables and figures, and drafted portions of the Results section.
NV conducted the literature review and co-drafted the Background. All
authors reviewed and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
The authors wish to acknowledge Warren Stevens, David Jeffries, and
Hongmei Yang for their work on PSI’s DALYs averted models, and their
continued updates to the models. In addition, Hongmei Yang is appreciated
for her review of the text that refers to her models. We also thank Amy
Ratcliffe and Steven Chapman for reviewing manuscript drafts, and Sue
Duvall for revising the manuscript as scientific editor. Finally, we appreciate
the funding support that Population Services International provided for this
research.
Declarations
This article is part of the supplement of BMC Public Health Volume 13,
Supplement 2, 2013: Use of health impact metrics for programmatic
decision making in global health. Population Services International, a
registered non-profit organization, provided the funding for the publication
of this supplement. The full contents of the supplement are available online
at http://www.biomedcentral.com/bmcpublichealth/supplements/13/S2.
Author details
1Population Services International, 1120 19th Street NW, Suite 600,
Washington, DC, 20036. 2Population Services International/Laos, T4 Road,
Unit 16, Donkoi Village, Vientiane, Lao PDR, PO Box 872.
Published: 17 June 2013
References
1. The Global Fund: Performance Based Funding. [http://www.
theglobalfund.org/en/activities/pbf/].
2. Department for International Development: Research and Evidence.
[http://www.dfid.gov.uk/What-we-do/Research-and-evidence].
3. US Agency for International Development: Performance-based
Incentives Primer for USAID Missions. [http://pdf.usaid.gov/pdf_docs/
PNADX747.pdf].
4. The World Bank: Program-for-Results Financing. [http://web.worldbank.
org/WBSITE/EXTERNAL/PROJECTS/0,,contentMDK:23215867~pagePK:41367~
piPK:51533~theSitePK:40941,00.html].
5. Murray CJ, Frenk J: Health metrics and evaluation: strengthening the
science. Lancet 2008, 371(9619):1191-9.
6. McKenna M, Marks J: Commentary on the uses of summary measures of
population health. In Summary measures of population health: concepts,
ethics, measurement and applications. Geneva: World Health Organization;
Murray CJ, Salomon JA, Mathers CD, Lopez, AD 2002:67-74.
7. Murray CJ, Salomon JA, Mathers CD, Lopez AD: Summary measures of
population health: Conclusions and recommendations. In Summary
measures of population health: concepts, ethics, measurement and
applications. Geneva: World Health Organization;Murray CJ, Salomon JA,
Mathers CD, Lopez, AD 2002:731-756.
8. Currie CS, Floyd K, Williams BG, Dye C: Cost, affordability and cost-
effectiveness of strategies to control tuberculosis in countries with high
HIV prevalence. BMC Public Health 2005, 5:130.
9. Kahn JG, Muraguri N, Harris B, Lugada E, Clasen T, Grabowsky M, Mermin J,
Shariff S: Integrated HIV testing, malaria, and diarrhea prevention
campaign in Kenya: modeled health impact and cost-effectiveness. PLoS
One 2012, 7(2):e31316.
10. Abimbola TO, Marston BJ: The cost-effectiveness of cotrimoxazole in
people with advanced HIV infection initiating antiretroviral therapy in
sub-Saharan Africa. J Acquir Immune Defic Syndr 2012, 60(1):e8-e14.
11. Stover J, Bertrand JT, Shelton JD: Empirically based conversion factors for
calculating couple-years of protection. Eval Rev 2000, 24(1):3-46, Review.
12. The Respond Project. New Developments in the Calculation and Use of
Couple-Years of Protection (CYP) and Their Implications for the Evaluation of
Family Planning Programs: Meeting Highlights Washington, DC; 2011.
13. Murray CJ, Lopez AD: Progress and directions in refining the global
burden of disease approach: a response to Williams. Health Econ 2000,
9(1):69-82.
14. Murray CJ, Frenk J: Summary measures of population health in the
context of the WHO framework for health system performance
assessment. In Summary measures of population health: concepts, ethics,
measurement and applications. Geneva: World Health Organization; Murray
CJ, Salomon JA, Mathers CD, Lopez, AD 2002:1-11.
15. Wolfson MC: On the uses of summary measures of population health. In
Summary measures of population health: concepts, ethics, measurement and
applications. Geneva: World Health Organization;Murray CJ, Salomon JA,
Mathers CD, Lopez, AD 2002:61-66.
16. Mahapatra P: Priority-setting in the health sector and summary measures
of population health. In Summary measures of population health: concepts,
ethics, measurement and applications. Geneva: World Health Organization;
Murray CJ, Salomon JA, Mathers CD, Lopez, AD 2002:83-90.
17. The World Bank: World Development Report 1993: Investing in Health
Washington, DC: World Bank Oxford University Press; 1993.
18. Murray CJ, Lopez AD: Quantifying disability: data, methods and results.
Bull World Health Organ 1994, 72(3):481-94.
19. Michaud CM, Murray CJ, Bloom BR: Burden of disease - implications for
future research. JAMA 2001, 285(5):535-9.
20. Naghavi M, Abolhassani F, Pourmalek F, Lakeh M, Jafari N, Vaseghi S,
Mahdavi Hezaveh N, Kazemeini H: The burden of disease and injury in
Iran 2003. Popul Health Metr 2009, 7:9.
21. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL: Measuring the
global burden of disease and risk factors, 1990-2001. In Global Burden of
Disease and Risk Factors. Washington, DC: World Bank;Lopez AD, Mathers
CD, Ezzati M, Jamison DT, Murray CJL 2006:1-13.
22. Murray CJ, Lopez AD, Jamison DT: The global burden of disease in 1990:
summary results, sensitivity analysis and future directions. Bull World
Health Organ 1994, 72(3):495-509.
23. Labeaud AD, Bashir F, King CH: Measuring the burden of arboviral
diseases: the spectrum of morbidity and mortality from four prevalent
infections. Popul Health Metr 2011, 9(1):1.
24. Gaunt ER, Harvala H, McIntyre C, Templeton KE, Simmonds P: Disease
burden of the most commonly detected respiratory viruses in
hospitalized patients calculated using the disability-adjusted life year
(DALY) model. J Clin Virol 2011, 52(3):215-21.
25. Krishnamoorthy K, Harichandrakumar KT, Krishna Kumari A, Das LK: Burden
of chikungunya in India: estimates of disability-adjusted life years (DALY)
lost in 2006 epidemic. J Vector Borne Dis 2009, 46(1):26-35.
26. Mathers CD, Ezzati M, Lopez AD: Measuring the burden of neglected
tropical diseases: the global burden of disease framework. PLoS Negl
Trop Dis 2007, 1(2):e114.
27. Miraglia SG, Saldiva PH, Böhm GM: An evaluation of air pollution health
impacts and costs in São Paulo, Brazil. Environ Manage 2005, 35(5):667-76.
28. Burton MJ, Mabey DC: The global burden of trachoma: a review. PLoS
Negl Trop Dis 2009, 3(10):e460.
29. Fèvre EM, Wissmann BV, Welburn SC, Lutumba P: The burden of human
African trypanosomiasis. PLoS Negl Trop Dis 2008, 2(12):e333.
30. Baltussen R, Floyd K, Dye C: Cost-effectiveness analysis of strategies for
tuberculosis control in developing countries. BMJ 2005, 331(7529):1364.
31. Bos JM, Postma MJ: The economics of HIV vaccines: projecting the
impact of HIV vaccination of infants in sub-Saharan Africa.
Pharmacoeconomics 2001, 19(9):937-46.
32. Broughton EI, Gomez I, Nuñez O, Wong Y: Cost-effectiveness of improving
pediatric hospital care in Nicaragua. Rev Panam Salud Publica 2011,
30(5):453-60.
33. de Vocht F, Higgerson J, Oliver K, Verma A: Incorporating uncertainty in
aggregate burden of disease measures: an example of DALYs-averted
Longfield et al. BMC Public Health 2013, 13(Suppl 2):S2
http://www.biomedcentral.com/1471-2458/13/S2/S2
Page 12 of 13
by a smoking cessation campaign in the UK. J Epidemiol Community
Health 2011, 65(9):751-6.
34. Gosselin RA, Thind A, Bellardinelli A: Cost/DALY averted in a small hospital
in Sierra Leone: what is the relative contribution of different services?
World J Surg 2006, 30(4):505-11.
35. Griffiths UK, Wolfson LJ, Quddus A, Younus M, Hafiz RA: Incremental cost-
effectiveness of supplementary immunization activities to prevent
neonatal tetanus in Pakistan. Bull World Health Organ 2004, 82(9):643-51.
36. Hogan DR, Baltussen R, Hayashi C, Lauer JA, Salomon JA: Cost-effectiveness
analysis of strategies to combat HIV/AIDS in developing countries. BMJ
2005, 331(7530):1431-7.
37. Hu D, Bertozzi SM, Gakidou E, Sweet S, Goldie SJ: The costs, benefits, and
cost-effectiveness of interventions to reduce maternal morbidity and
mortality in Mexico. PLoS One 2007, 8: e750.
38. Kim SY, Sweet S, Slichter D, Goldie SJ: Health and economic impact of
rotavirus vaccination in GAVI-eligible countries. BMC Public Health 2010,
10:253, May 14.
39. Lohse N, Marseille E, Kahn JG: Development of a model to assess the
cost-effectiveness of gestational diabetes mellitus screening and lifestyle
change for the prevention of type 2 diabetes mellitus. Int J Gynaecol
Obstet 2011, 115(Suppl 1):S20-5.
40. Muhundhakumar D: Estimating the impact of surgical interventions in
global health through the DALY framework. Cambridge Medicine Journal
[http://www.cambridgemedicine.org/news/1302279246].
41. te Velde SJ, Lennert Veerman J, Tak NI, Bosmans JE, Klepp KI, Brug J:
Modeling the long term health outcomes and cost-effectiveness of two
interventions promoting fruit and vegetable intake among
schoolchildren. Econ Hum Biol 2011, 9(1):14-22.
42. Kahn JG, Muraguri N, Harris B, Lugada E, Clasen T, Grabowsky M, Mermin J,
Shariff S: Integrated HIV testing, malaria, and diarrhea prevention
campaign in Kenya: modeled health impact and cost-effectiveness. PLoS
One 2012, 7(2):e31316.
43. Yang H, Duvall S, Ratcliffe A, Jeffries D, Stevens W: Modeling health impact
of global health programs implemented by Population Services
International. BMC Public Health 2013, 13(Suppl 2):S3.
44. Population Services International Research & Metrics: First round HIV/STI
prevalence and behavioral tracking survey among male-to-female
transgenders in Vientiane capital and Savannakhet, Lao PDR. TRaC
Summary Report 2010.
45. Stover J, McKinnon R, Winfrey B: Spectrum: A model platform for linking
of maternal and child survival interventions with AIDS, family planning
and demographic projections. Int J Epidemiol 2010, 39:i7-i10.
46. Walker N, Fischer-Walker C, Bryce J, Bahl R, Cousens S, CHERG Review
Groups on Intervention Effects: Standards for CHERG reviews of
intervention effects on child survival. Int J Epidemiol 2010, 39:i21-31.
47. Fox MJ, Martorell R, van den Broek N, Walker N: Assumptions and
methods in the Lives Saved Tool (LiST). BMC Public Health 2011,
11(Suppl 3):I1.
doi:10.1186/1471-2458-13-S2-S2
Cite this article as: Longfield et al.: Putting health metrics into practice:
using the disability-adjusted life year for strategic decision making. BMC
Public Health 2013 13(Suppl 2):S2.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Longfield et al. BMC Public Health 2013, 13(Suppl 2):S2
http://www.biomedcentral.com/1471-2458/13/S2/S2
Page 13 of 13
